Position your portfolio before the wall of “dumb money” floods in…
This “Tiny” Biotech Stock Could Be Massive for Early Investors…
Enter your email below to get your free early investor report on Cybin, Inc.
If you’re looking for early investment opportunities in the promising medical psychedelic research space then keep your eyes on Cybin Inc.
Meet the CEO…
A 30 year veteran in the healthcare sector, Doug Drysdale has built and turned-around 4 pharmaceutical companies, completed 15 corporate acquisitions, and has raised $4 billion of both public and private capital.

And according to Drysdale, Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) disrupting one of the largest fields in modern medicine is a key component of their growth strategy…

We are focused on addressing the mental health crisis and transforming the treatment landscape.
- Doug Drysdale
, Cybin CEO
Don’t expect Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) to remain “tiny” once the news about their revolutionary medical breakthroughs goes mainstream.

Investors looking for early opportunities in psychedelic medicine should move quickly on Cybin Inc. (NEO:CYBN)(OTCQB:CLXPF) and establish
a position before the wall of retail and institutional money starts moving in on the opportunity.

Be part of the Future
Enter your email below to get your free early investor report on Cybin, Inc.

Company Overview

  • We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.
 
  • C$88M raised to date. Well-funded to progress clinical trials, M&A and IP strategies.
 
  • 4 active drug programs targeting Major Depressive Disorder, Alcohol Use Disorder and Therapy Resistant Psychiatric Disorders (CYB001, CYB003, CYB004, CYB005).
 
  • Phase II approval to commence clinical trial on CYB001 which is targeting Major Depressive Disorder.
  • 12 patent filings and growing which cover Novel psychedelic compounds, Integration of delivery platforms, Methods of use in psychiatric indications, Drug discovery pipeline of modified and novel ergolines, tryptamines and phenethylamines.
 
  • 50+ pre-clinical studies completed and progressing lead programs toward FDA IND filings
 
  • Experienced leadership and scientific team that has previously successfully brought multiple drugs to market, collectively involved in 37 exits and overseen 60+ IND programs with the FDA
We’re on a mission to
revolutionize mental healthcare.
Be part of the Future
Enter your email below to get your free early investor report on Cybin, Inc.